Reference(s)
Click here to return to the Reference Table

Category: Other Neoplasms
Cancer type: Glioblastomas/Astrocytomas
Descriptor: Met expression


Reference Number: 186
Koochekpour, S. et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57, 5391-8 (1997).
PubMed link      E-mail link

Reference Number: 187
Kunkel, P. et al. Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Neuro-oncol 3, 82-8 (2001).
PubMed link      E-mail link

Reference Number: 188
Lamszus, K., Laterra, J., Westphal, M. & Rosen, E. M. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci 17, 517-30 (1999).
PubMed link      E-mail link

Reference Number: 189
Moriyama, T., Kataoka, H., Koono, M. & Wakisaka, S. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review). Int J Mol Med 3, 531-6 (1999).
PubMed link      E-mail link

Reference Number: 190
Hirose, Y. et al. Immunohistochemical examination of c-Met protein expression in astrocytic tumors. Acta Neuropathol (Berl) 95, 345-51. (1998).
PubMed link      E-mail link

Reference Number: 191
Nabeshima, K. et al. Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study. Histopathology 31, 436-43. (1997).
PubMed link      E-mail link

Reference Number: 519
Ma Y, Yuan RQ, Fan S, Hu C, Goldberg ID, Laterra JJ, Rosen EM. Identification of genes that modulate sensitivity of U373MG glioblastoma cells to cis-platinum. Anticancer Drugs. 17, 733-51 (2006)
PubMed link      E-mail link

Reference Number: 542
Eckerich C, Zapf S, Fillbrandt R, Loges S, Westphal M, Lamszus K. Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration. Int J Cancer. 121, 276-83 (2007)
PubMed link      E-mail link

Reference Number: 622
Tseng JR, Kang KW, Dandekar M, Yaghoubi S, Lee JH, Christensen JG, Muir S, Vincent PW, Michaud NR, Gambhir SS. Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J Nucl Med. 49, 129-34 (2008)
PubMed link      E-mail link

Reference Number: 695
Kong DS, Song SY, Kim DH, Joo KM, Yoo JS, Koh JS, Dong SM, Suh YL, Lee JI, Park K, Kim JH, Nam DH. Prognostic significance of c-Met expression in glioblastomas. Cancer. 115, 140-8 (2009)
PubMed link      E-mail link

Reference Number: 730
Kongkham PN, Northcott PA, Ra YS, Nakahara Y, Mainprize TG, Croul SE, Smith CA, Taylor MD, Rutka JT. An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. Cancer Res. 68, 9945-53 (2008)
PubMed link      E-mail link

Reference Number: 731
Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi E, Xu E, Berghuis B, Daugherty J, Grabinski T, Toro J, Giambernardi T, Skinner RS, Gross M, Hudson E, Kort E, Lengyel E, Ventura A, West RA, Xie Q, Hay R, Woude GV, Cao B. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol. 17, 57-67 (2009)
PubMed link      E-mail link

Reference Number: 866
Pei Z, Sun P, Huang P, Lal B, Laterra J, Watkins PA. Acyl-CoA synthetase VL3 knockdown inhibits human glioma cell proliferation and tumorigenicity. Cancer Res. 69, 9175-82 (2009)
PubMed link      E-mail link

Reference Number: 940
Liu W, Fu Y, Xu S, Ding F, Zhao G, Zhang K, Du C, Pang B, Pang Q. c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme. J Clin Neurosci. 18, 119-21 (2011)
PubMed link      E-mail link

Reference Number: 1060
Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, De Giorgi V, Wang E, Kefene L, Su Y, Essenburg C, Kaufman DW, DeKoning T, Enter MA, O'Rourke TJ, Marincola FM, Vande Woude GF. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A. 109, 570-5 (2012)
PubMed link      E-mail link

Reference Number: 1190
Jun HJ, Acquaviva J, Chi D, Lessard J, Zhu H, Woolfenden S, Bronson RT, Pfannl R, White F, Housman DE, Iyer L, Whittaker CA, Boskovitz A, Raval A, Charest A. Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene. 31, 3039-50 (2012)
PubMed link      E-mail link

Reference Number: 1215
Joo KM, Jin J, Kim E, Ho Kim K, Kim Y, Gu Kang B, Kang YJ, Lathia JD, Cheong KH, Song PH, Kim H, Seol HJ, Kong DS, Lee JI, Rich JN, Lee J, Nam DH. MET signaling regulates glioblastoma stem cells. Cancer Res. 72, 3828-38 (2012)
PubMed link      E-mail link

Reference Number: 1221
De Bacco F, Casanova E, Medico E, Pellegatta S, Orzan F, Albano R, Luraghi P, Reato G, D'Ambrosio A, Porrati P, Patanè M, Maderna E, Pollo B, Comoglio PM, Finocchiaro G, Boccaccio C. The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res. 72, 4537-50 (2012)
PubMed link      E-mail link

Reference Number: 1263
Galavotti S, Bartesaghi S, Faccenda D, Shaked-Rabi M, Sanzone S, McEvoy A, Dinsdale D, Condorelli F, Brandner S, Campanella M, Grose R, Jones C, Salomoni P. The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene. 32, 699-712 (2013)
PubMed link      E-mail link

Reference Number: 1268
Yang H, Lee HW, Kim Y, Lee Y, Choi YS, Kim KH, Jin J, Lee J, Joo KM, Nam DH. Radiosensitization of brain metastasis by targeting c-MET. Lab Invest. 93, 344-53 (2013)
PubMed link      E-mail link

Reference Number: 1275
Miekus K, Kijowski J, Sekula M, Majka M. 17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion. Oncol Rep. 28, 1903-9 (2012)
PubMed link      E-mail link

Reference Number: 1329
Kim KH, Seol HJ, Kim EH, Rheey J, Jin HJ, Lee Y, Joo KM, Lee J, Nam DH. Wnt/ß-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro Oncol. 15, 161-71 (2013)
PubMed link      E-mail link

Reference Number: 1350
Jahangiri A1, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen SM, Bergers G, Aghi MK. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res. 19, 1773-83 (2013)
PubMed link      E-mail link

Reference Number: 1410
Lee SJ1, Seol HJ, Lee HW, Kang WY, Kang BG, Jin J, Jo MY, Jin Y, Lee JI, Joo KM, Nam DH. Gene silencing of c-Met leads to brain metastasis inhibitory effects. Clin Exp Metastasis. 30, 845-54 (2013)
PubMed link      E-mail link

Reference Number: 1423
Murray DW1, Didier S2, Chan A2, Paulino V3, Van Aelst L4, Ruggieri R2, Tran NL3, Byrne AT5, Symons M2. Guanine nucleotide exchange factor Dock7 mediates HGF-induced glioblastoma cell invasion via Rac activation. Br J Cancer. 110, 1307-15 (2014)
PubMed link      E-mail link

Reference Number: 1469
Byeon SJ, Cho HJ, Baek HW, Park CK, Choi SH, Kim SH, Kim HK, Park SH. Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics. Hum Pathol. 45, 611-20 (2014)
PubMed link      E-mail link

Reference Number: 1544
Jun HJ, Bronson RT, Charest A. Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma. Stem Cells. 32, 338-48 (2013)
PubMed link      E-mail link

Reference Number: 1556
Olmez OF, Cubukcu E, Evrensel T, Kurt M, Avci N, Tolunay S, Bekar A, Deligonul A, Hartavi M, Alkis N, Manavoglu O. The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme. Clin Transl Oncol. 16, 173-7 (2014)
PubMed link      E-mail link

Reference Number: 1557
Basilico C, Hultberg A, Blanchetot C, de Jonge N, Festjens E, Hanssens V, Osepa SI, De Boeck G, Mira A, Cazzanti M, Morello V, Dreier T, Saunders M, de Haard H, Michieli P. Four individually druggable MET hotspots mediate HGF-driven tumor progression. J Clin Invest. 124, 3172-86 (2014)
PubMed link      E-mail link

Reference Number: 1648
Camacho CV, Todorova PK, Hardebeck MC, Tomimatsu N, Gil del Alcazar CR, Ilcheva M, Mukherjee B, McEllin B, Vemireddy V, Hatanpaa K, Story MD, Habib AA, Murty VV, Bachoo R, Burma S. DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification. Oncogene. 34, 1064-72 (2015)
PubMed link      E-mail link

Reference Number: 1703
Furcht CM, Buonato JM, Skuli N, Mathew LK, Muñoz Rojas AR, Simon MC, Lazzara MJ. Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells. J Cell Sci. 127(Pt 16), 3555-67 (2014)
PubMed link      E-mail link

Reference Number: 1710
Luo H, Hong H, Slater MR, Graves SA, Shi S, Yang Y, Nickles RJ, Fan F, Cai W PET of c-Met in Cancer with 64Cu-Labeled Hepatocyte Growth Factor. J Nucl Med. 56, 758-63 (2015)
PubMed link      E-mail link

Reference Number: 1748
Wang X, Huang X, Yang Z, Gallego-Perez D, Ma J, Zhao X, Xie J, Nakano I, Lee LJ. Targeted delivery of tumor suppressor microRNA-1 by transferrin-conjugated lipopolyplex nanoparticles to patient-derived glioblastoma stem cells. Curr Pharm Biotechnol. 15, 839-46 (2014)
PubMed link      E-mail link

Reference Number: 1894
Lee JS, Oh E, Yoo JY, Choi KS, Yoon MJ, Yun CO. Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells. Oncotarget. 6, 4051-65 (2015)
PubMed link      E-mail link